Compare Centrus Energy Corp (LEU) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Centrus Energy Corp vs Natera Inc. Common Stock — how do they compare? Centrus Energy Corp trades at $117.36 (market cap $2.75B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 20.7× Centrus Energy Corp's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Centrus Energy Corp for 31 Days and Natera Inc. Common Stock for 0 Days on average.
| LEU | NTRA | |
|---|---|---|
Market Cap | $2.75B | $57.03B |
Volume | 573,041 | 1,131,157 |
Sector | Energy | Health |
52-Week High | $436.00 | $425.64 |
52-Week Low | $119.95 | $179.42 |
Typical Hold Time | 31 Days | 0 Days |
Enterprise Value | $2.06B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Centrus Energy (LEU) trades at $134.28, down 0.76% on the day, with technical indicators showing a bearish trend. The company maintains strong fundamentals with $448.70M revenue and $77.80M net income for 2025, though profitability declined in 2026. Recent multi-year HALEU supply contracts with Antares and Radiant highlight Centrus' strategic position in the nuclear fuel market as the only US-licensed HALEU producer.
The stock presents a compelling growth opportunity in nuclear energy infrastructure with 46% analyst buy ratings and $218.10 consensus price target, but faces execution risks amid high valuation multiples (P/E 71.05) and recent earnings volatility. Key risks include dependency on nuclear policy support and competitive pressures in uranium enrichment.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
